Compare AbbVie Inc (ABBV) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Thomson Reuters Corp — how do they compare? AbbVie Inc trades at $253.95 (market cap $449.91B), while Thomson Reuters Corp trades at $88.76 (market cap $39.64B). The key difference: AbbVie Inc is far larger — about 11.3× Thomson Reuters Corp's market cap, and Thomson Reuters Corp pays the higher dividend (2.89%). Which is the better fit depends on your goals.
| ABBV | TRI | |
|---|---|---|
Market Cap | $449.91B | $39.64B |
Sector | Health | Industrials |
52-Week High | $261.07 | $214.21 |
52-Week Low | $184.85 | $76.55 |
Enterprise Value | $513.38B | $41.59B |
Dividend Yield | 2.72% | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
Thomson Reuters (TRI) trades at $90.76, up 1.74% with bullish technical indicators and strong analyst support. The company reported Q1 2026 EPS of $1.23, beating estimates, while revenue reached $7.48B in 2025. Recent corporate actions include a special dividend and reverse stock split. Technical analysis shows resistance near $92 with RSI indicating potential overbought conditions.
Outlook remains positive with a consensus price target of $129.96, though risks include AI implementation challenges and competitive pressures. Revenue growth is steady, but net income margin compression from 39.66% in 2023 to 20.09% in 2025 warrants monitoring. Institutional sentiment is bullish with 51.85% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
